Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...

(Reuters) - European shares jumped on Wednesday after Ukraine accepted the U.S.' proposal for a 30-day ceasefire with Russia, ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

Some companies, like Zealand Pharma and Roche (RHHBY), are developing next-generation treatments with stronger weight-loss effects. Others, like Hims & Hers (HIMS), betted on more affordable off ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Roche's stock rallied in Europe, while ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...